Form 4: UroGen Pharma CMO Plans 10,000 Share Sale in November 2025

UroGen Pharma's Chief Medical Officer, Mark Schoenberg, has filed a Form 4 indicating a planned sale of 10,000 ordinary shares in November 2025 under a pre-arranged 10b5-1 trading plan.

Summary

• Mark Schoenberg, Chief Medical Officer of UroGen Pharma Ltd. (URGN), filed a Form 4 reporting a planned transaction.
• The transaction involves the disposition (sale) of 10,000 ordinary shares.
• The transaction is scheduled to occur on November 19, 2025.
• The shares are planned to be sold at a weighted average price of approximately $25.00 per share, with sales occurring between $25.00 and $25.02.
• This sale is being conducted pursuant to a Rule 10b5-1(c) trading plan, which was adopted on August 15, 2025.
• Following this planned transaction, Mark Schoenberg will beneficially own 139,025 ordinary shares directly.

Sentiment

Score: 5

Explanation: The sentiment is neutral as this is a pre-planned insider sale under a 10b5-1 plan, which typically indicates a routine financial management decision rather than a reaction to company-specific news.

Positives

• The transaction is part of a pre-arranged Rule 10b5-1(c) trading plan, adopted on August 15, 2025, indicating a scheduled, non-event-driven sale rather than a reaction to new, non-public information.

Negatives

• An insider sale, even if pre-planned, represents a reduction in the reporting person's direct ownership in the company.

Future Outlook

This filing reports a future planned insider transaction and does not contain forward-looking statements or guidance regarding the company's operational or financial performance.

Industry Context

This Form 4 filing reports a routine insider transaction and does not provide information relevant to broader industry trends or competitive landscape.

Stakeholder Impact

• Shareholders may note the planned reduction in direct ownership by a key executive, though the pre-planned nature under Rule 10b5-1 mitigates concerns about immediate market impact.

Key Dates

Keywords

UroGen Pharma, URGN, Insider Transaction, Form 4, Stock Sale, Chief Medical Officer, Mark Schoenberg, 10b5-1 Plan